The use of clozapine in an individual with moderate intellectual disability, aggressive behaviour and resistant psychosis

Irish Journal of Psychological Medicine

Volumn 16, Issue 1, 1999, Pages 32-33

  Kamal, Manzar ^a   Kelly, Mary ^a  

^a St Mary's   (Ireland)

Author keywords

Clozapine; Moderate intellectual disability; Treatment resistant psychosis

Indexed keywords

BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; THIORIDAZINE; ZUCLOPENTHIXOL;

ADULT; AGGRESSION; ARTICLE; AUTOMUTILATION; CASE REPORT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HALLUCINATION; HOSTILITY; HUMAN; INTELLECTUAL IMPAIRMENT; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033051423     PISSN: 07909667     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0790966700005024     Document Type: Article

References (8)

1. 1. Sovner R. Is it behaviour or mental illness? Paper presented to PBA Consultants. Pittsburgh: 1991 October.
2. 2. Vynke J. The treatment of behaviour disorders in idiocy and imbecility with clozapine. Pharmacopsychiatry 1974; 7: 225-9.
3. 3. Cohen SA, Underwood MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry 1994; 55: 440-4.
4. 4. Sajatovic M et al. The use of clozapine in borderline intellectual functioning and mentally retarded schizophrenic patients. Compr Psychiatry 1994; 35: 29-33.
5. 5. Pary RJ. Clozapine in three individuals with mild mental retardation and treatment refractory psychiatric disorders. Ment Retard 1994; 32: 323-7.
6. 6. Boachie A, McGinnity M. Use of clozapine in a mental hospital - report of the first 17 patients. Ir J Psych Med 1997; 14(1): 16-9.
7. 7. Breese GR et al. Behavioural differences between neonatal and six adult hydroxydopamine treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 1984a; 231: 343-54.
8. 8. Breese GR et al. Pharmacological evaluation of SCH-12679: Evidence of an in vivo antagonism of D1 dopamine receptors. J Pharmacol Exp Ther 1990; 252: 558-76.